FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) who are interested in information on Pulmozyme® (dornase alpha). This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.

To view the EU SmPC, click hereopens in a new tab

If you are a US healthcare professional, click here

If you are a US patient, click here

What is Pulmozyme?

What is Pulmozyme?

Pulmozyme®(dornase alfa) is indicated for the management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted and over 5 years of age to improve pulmonary function.1

Consider Pulmozyme for the management of cystic fibrosis.
An agent with a distinct mechanism of action in helping to clear mucus 1, 3-6

Countries where Pulmozyme is approved

Pulmozyme is approved in > 65 countries. Please see the map below for further information.

world map

1. Pulmozyme SmPC, Electronic Medicines Compendium, accessed 10/8/18

3. Harms  HK et al. Dnase International Study Group. Multicenter, open-label study of recombinant human Dnase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol. 1998; 23(3): 155-161.

4. King, M. Mucolytics and mucus clearance. In Rubin BK, van der Sxhans CP, eds. Therapy for Mucus-Clearance Disorders. New Yoirk, NY: Marcel Dekker Inc, 2004:201-224. 

5. Chmiel, JF, Kanstan MW. Anti-inflammatory medication for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med. 2005; 4(4):255-273.

6. Puchelle E et al. Physical and functional properties of airway secretions in cystic fibrosis – therapeutic approaches. Respiration. 1995; 62(suppl 1) 2-12.

35. The Pharma Letter. EU gives go-ahead to Pulmozyme. https://www.thepharmaletter.com/article/eu-gives-go-ahead-to-pulmozymeopens in a new tab. Accessed March 29, 2017